Unilife and Novartis, Hikma, AstraZeneca, Sanofi

Company: Unilife ($UNIS)
Partners: Novartis ($NVS), Hikma, AstraZeneca ($AZN), Sanofi ($SNY)
Technology: Injectables
Amount: Novartis, undisclosed; Hikma, $40 million; AZ, undisclosed; Sanofi, 150 million units per year

The scoop: Injectables maker Unilife boasted a full year of partnerships with some of the biggest names in the industry. In 2013, the company signed on with Novartis, Hikma, AstraZeneca's MedImmune and Sanofi, offering each of the outfits a deal that gives them access to its several lines of injectable delivery devices for large molecules.

The Novartis and AstraZeneca deals went down for undisclosed amounts, but the deal with Hikma gave Unilife $40 million and a 15-year contract. For Sanofi, it's a 10-year contract for at least 150 million units a year.

The technology differs for each deal. Unilife has the capacity to tailor its devices for the needs of each partner, Unilife CEO Alan Shortall told FierceDrugDelivery in December. Novartis, for instance, signed on for a delivery system to inject an unspecified early-stage pipeline drug using customized technology, in a deal that would affect "a significant portion of the U.S. and the world."

"This is the delivery of a biologic directly into the organ in the body," Shortall said at the time. "The other solution is to carry out surgery, and Novartis came to us to come up with an alternative, a new route of delivery."

A wearable injector caught MedImmune's interest, and Unilife is also customizing its devices for specific drugs in the MedImmune pipeline.

For more:
Unilife bags Novartis deal for injectable tech
Unilife signs $40M deal to supply Hikma with prefilled syringes
MedImmune taps Unilife for wearable biologic injectable tech

Unilife and Novartis, Hikma, AstraZeneca, Sanofi

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.